Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000210668 | SCV000262875 | uncertain significance | Inborn genetic diseases | 2015-12-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000651170 | SCV000773020 | uncertain significance | Cryptosporidiosis-chronic cholangitis-liver disease syndrome | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 156 of the IL21R protein (p.Tyr156Cys). This variant is present in population databases (rs745372589, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with IL21R-related conditions. ClinVar contains an entry for this variant (Variation ID: 225007). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000651170 | SCV003813366 | uncertain significance | Cryptosporidiosis-chronic cholangitis-liver disease syndrome | 2020-02-14 | criteria provided, single submitter | clinical testing |